Article info

Download PDFPDF
Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients

Authors

  • Tingting Sun Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany; PubMed articlesGoogle scholar articles
  • Ilary Ruscito Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany;Department of Gynecology, Obstetrics, and Urology,Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy; PubMed articlesGoogle scholar articles
  • Desislava Dimitrova Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany; PubMed articlesGoogle scholar articles
  • Radoslav Chekerov Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany; PubMed articlesGoogle scholar articles
  • Hagen Kulbe Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany; PubMed articlesGoogle scholar articles
  • Udo Baron Ivana Türbachova Laboratory for Epigenetics, Epiontis GmbH, Berlin, Germany; PubMed articlesGoogle scholar articles
  • Véronique Blanchard Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité Medical University, Berlin, Germany; and PubMed articlesGoogle scholar articles
  • Pierluigi Benedetti Panici Department of Gynecology, Obstetrics, and Urology, PubMed articlesGoogle scholar articles
  • Silvia Darb-Esfahani Institute of Pathology, Campus Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany. PubMed articlesGoogle scholar articles
  • Jalid Sehouli Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany; PubMed articlesGoogle scholar articles
  • Sven Olek Ivana Türbachova Laboratory for Epigenetics, Epiontis GmbH, Berlin, Germany; PubMed articlesGoogle scholar articles
  • Elena Ioana Braicu Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany; PubMed articlesGoogle scholar articles
  1. Address correspondence and reprint requests to Elena Ioana Braicu, Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany. E-mail: Elena.Braicu@charite.de.

Citation

Sun T, Ruscito I, Dimitrova D, et al
Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients

Publication history

  • Received March 20, 2017
  • First published October 1, 2017.
Online issue publication 
October 01, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.